Management of XXXX : an anti-light-chain approach.

@entity1 @entity8 @entity5507 @entity1582 @entity177 @entity810 @entity1011
This report describes the course of 23 @entity1 with @entity1582 and severe @entity177 treated with a combination of plasmapheresis, chemotherapy, and supportive measures. Eight of ten @entity1 with @entity810 ( @entity810 ) obtained recovery of renal function, and in five of them serum @entity1011 concentration returned to normal. The remaining two @entity1 died before the effect of treatment could be evaluated. Eleven of 13 @entity1 with @entity177 ( @entity177 ) had substantial, albeit incomplete, improvement in renal function. The extent of functional recovery appeared to depend on the type of @entity8 , probably related to the duration of exposure to light chains. The median survival of the whole series of @entity1 was 9 months, and five @entity1 lived longer than 3 years. No clear-cut difference in survival was found between the group with @entity810 and that with @entity177 , although the latter presented higher values of serum @entity1011 at the time of diagnosis and @entity177 after the completion of treatment. Moreover, no significantly different survival times were found when the group with complete recovery of renal function was compared to that with minor improvement. Thus, @entity177 , with the availability of effective forms of treatment of @entity5507 , did not play a major prognostic role in our series. In contrast, the response to chemotherapy appeared to be the outstanding factor conditioning the duration of survival in these @entity1 .
